“Cost Effectiveness of Pembrolizumab Vs Chemotherapy As First-Line Treatment for Metastatic NSCLC That Expresses High Levels of PD-L1 in Switzerland”. 2019. Swiss Medical Weekly 149 (5152): w20170. https://doi.org/10.4414/smw.2019.20170.